CinCor Pharma Current Cash

The latest current cash for CINC is $290M as of September 2022. That compares with $140M in the prior-year period — up 106.5% year over year. Investors often review this figure alongside CinCor Pharma's historical trend and sector peers before judging valuation or financial health.

Over the past year, CINC's current cash moved from $140M to $290M — a 106.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in CinCor Pharma's operating scale or balance-sheet position.

A current cash figure of $290M for CINC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CINC's current cash ($290M), review year-over-year change from $140M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.